Collection / Tirzepatide 20mg
Tirzepatide 20mg
Tirzepatide is a dual GIP and GLP-1 receptor agonist studied for glucose regulation and body-weight endpoints. Its two-receptor identity makes it a specific focus in metabolic-health research.
Simulation only · No real order or payment.
GIP and GLP-1 receptor dual agonist
Also known as: LY3298176
Human trialResearch & handling
Not for human or veterinary use. Storage, handling, identity and purity require verified batch documentation. No dosing or treatment advice is provided.
At a glance
Dual receptor signalling
GIP and GLP-1 pathways frame the molecule’s endocrine activity.
Glucose endpoints
SURPASS-1 examined HbA1c in adults with type 2 diabetes.
Body-weight endpoints
Weight changes belong to controlled trials and their manufactured intervention.
Explore the study context and sources below. For laboratory research only.
Studies & context
Studied in adults with type 2 diabetes for blood-glucose and body-weight endpoints; GIP and GLP-1 are receptor targets, not independent product benefits.
Human trialSURPASS-1 randomized 478 adults in a 40-week phase 3 trial; all studied tirzepatide arms improved HbA1c and body-weight endpoints versus placebo.
Study limitations
A defined type 2 diabetes population and manufactured trial intervention, not PEPTIVIA material.
Nausea, diarrhoea and vomiting were the most frequent adverse events, generally mild to moderate and transient.
Study limitations
Trial monitoring and findings do not establish safety of a catalogue vial or pen.
Published research is separate from PEPTIVIA identity, content, purity, sterility and batch documentation. No source-supplier report verifies PEPTIVIA material.